Physician profile
Rosekamal Mckinney
NPI 1457794885
$5,494.22
in general payments reported to CMS, 2019-2025
31 companies · $2,217 in 2025
The $2,217 reported for 2025 was more than what 96% of Addiction Medicine (Preventive Medicine) providers received nationally (typical 2025 total: $115).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $148 · 2021: $625 · 2022: $603 · 2023: $505 · 2024: $1,103 · 2025: $2,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,824.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $663.60 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $547.98 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $491.47 | 2019-2025 | Sublocade, Perseris |
| Lundbeck LLC | $460.56 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $407.96 | 2021-2025 | Fanapt |
| Alkermes, INC. | $367.70 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $335.22 | 2019-2025 | Ingrezza |
| Abbvie INC. | $281.53 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.36 | 2021-2025 | Caplyta |
| Orexo US, INC. | $230.79 | 2019-2025 | Zubsolv |
| Teva Pharmaceuticals USA, INC. | $205.39 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $176.05 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $135.52 | 2023-2025 | Auvelity |
| Edwards Lifesciences Corporation | $122.48 | 2022 | |
| Almatica Pharma LLC | $120.59 | 2021-2024 | Loreev Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $112.17 | 2025 | Cobenfy |
| Braeburn INC. | $100.66 | 2025 | Brixadi |
| Eisai INC. | $93.14 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $79.77 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $71.07 | 2019-2022 | |
| Neuronetics, INC. | $49.70 | 2020 | |
| Ironshore Pharmaceuticals INC. | $38.59 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $20.35 | 2025 | Qelbree |
| Tris Pharma INC | $20.25 | 2019 | |
| Bioxcel Therapeutics, INC. | $19.88 | 2023 | Igalmi |
| Jazz Pharmaceuticals INC. | $19.38 | 2021 | |
| Noven Therapeutics, LLC | $19.34 | 2024 | Secuado, Xelstrym |
| Bausch Health US, LLC | $19.05 | 2022 | |
| Vertical Pharmaceuticals, LLC | $18.88 | 2019 | |
| Merck Sharp & Dohme LLC | $14.19 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.60 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosekamal Mckinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.